Provided by Tiger Trade Technology Pte. Ltd.

Praxis Precision Medicines, Inc.

334.58
-3.9900-1.18%
Post-market: 336.161.58+0.47%16:34 EDT
Volume:173.53K
Turnover:58.76M
Market Cap:9.32B
PE:-26.01
High:348.00
Open:340.00
Low:334.00
Close:338.57
52wk High:392.70
52wk Low:37.25
Shares:27.85M
Float Shares:24.08M
Volume Ratio:0.71
T/O Rate:0.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-12.8634
EPS(LYR):-13.4758
ROE:-38.86%
ROA:-25.65%
PB:6.95
PE(LYR):-24.83

Loading ...

Praxis Precision Medicines (PRAX) Gets a Buy from Truist Financial

TIPRANKS
·
Jun 02

Piper Sandler Remains a Buy on Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 02

Deutsche Bank Adjusts Praxis Precision Medicines PT to $374 From $420, Maintains Buy Rating

MT Newswires Live
·
Jun 02

Guggenheim Sticks to Its Buy Rating for Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 02

S&P 500 Futures Fall In Premarket Trading; Hewlett Packard Ent, Marvell Technology Lead

Dow Jones
·
Jun 02

Wells Fargo Sticks to Its Hold Rating for Praxis Precision Medicines (PRAX)

TIPRANKS
·
Jun 02

Buy Rating Reaffirmed as Higher Relutrigine Pricing Assumptions Offset Vormatrigine Setback; $537 Price Target Maintained

TIPRANKS
·
Jun 02

Yazdi Maintains Buy on Praxis, Trims Price Target to $810 as Vormatrigine Outlook Softens but Core Pipeline Thesis Remains Intact

TIPRANKS
·
Jun 02

Praxis Precision Medicines Inc : TD Cowen Cuts Target Price to $510 From $554

THOMSON REUTERS
·
Jun 02

Praxis Precision price target lowered to $1,201 from $1,245 at H.C. Wainwright

TIPRANKS
·
Jun 02

Praxis Precision Medicines, Inc. : H.c. Wainwright Cuts Target Price to $1201 From $1245

THOMSON REUTERS
·
Jun 02

Praxis Precision Med Is Maintained at Buy by BTIG

Dow Jones
·
Jun 02

U.S. RESEARCH ROUNDUP-Edgewise Therapeutics, IBM, Rubrik

Reuters
·
Jun 02

Praxis Precision Medicines Inc : Baird Cuts Target Price to $400 From $433

THOMSON REUTERS
·
Jun 02

Praxis Precision Reassesses Vormatrigine After Mixed POWER1 Data

TIPRANKS
·
Jun 02

Praxis Precision Medicines's Seizure Treatment Fails to Meet Trial's Primary Endpoint

Dow Jones
·
Jun 02

Praxis Precision reports POWER1 study misses endpoint, pauses POWER2 enrollment

TIPRANKS
·
Jun 02

Praxis says POWER1 trial of vormatrigine in focal seizures misses primary endpoint

Reuters
·
Jun 02

Praxis Precision Medicines - Power1 Study Did Not Meet Primary Endpoint in Refractory Focal Onset Seizures

THOMSON REUTERS
·
Jun 02

Praxis Precision Medicines - Pauses Enrollment in Power2 Study to Reassess Vormatrigine Program

THOMSON REUTERS
·
Jun 02